CDC25B

Summary

CDC25B (cell division cycle 25B, HGNC:1726) is a protein-coding gene on chromosome 20p13, encoding M-phase inducer phosphatase 2 (P30305). Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. It is a selective cancer dependency (DepMap: 18.3% of cell lines).

CDC25B is a member of the CDC25 family of phosphatases. CDC25B activates the cyclin dependent kinase CDC2 by removing two phosphate groups and it is required for entry into mitosis. CDC25B shuttles between the nucleus and the cytoplasm due to nuclear localization and nuclear export signals. The protein is nuclear in the M and G1 phases of the cell cycle and moves to the cytoplasm during S and G2. CDC25B has oncogenic properties, although its role in tumor formation has not been determined. Multiple transcript variants for this gene exist.

Source: NCBI Gene 994 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 120 total
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 18.3% of screened cell lines
• MANE Select transcript: NM_021873

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1726
Approved symbol	CDC25B
Name	cell division cycle 25B
Location	20p13
Locus type	gene with protein product
Status	Approved
Aliases	MPIP2
Ensembl gene	ENSG00000101224
Ensembl biotype	protein_coding
OMIM	116949
Entrez	994

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 11 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000245960, ENST00000340833, ENST00000344256, ENST00000379598, ENST00000439880, ENST00000467519, ENST00000468979, ENST00000480816, ENST00000495915, ENST00000855779, ENST00000855780, ENST00000855781, ENST00000855782, ENST00000855783, ENST00000940254

RefSeq mRNA: 10 — MANE Select: NM_021873 NM_001287516, NM_001287517, NM_001287518, NM_001287519, NM_001287520, NM_001287522, NM_001287524, NM_004358, NM_021872, NM_021873

CCDS: CCDS13065, CCDS13066, CCDS13067, CCDS74700, CCDS74701

Canonical transcript exons

ENST00000245960 — 16 exons

Exon	Start	End
ENSE00001353605	3796310	3796731
ENSE00001869849	3804821	3806115
ENSE00003458661	3797622	3797749
ENSE00003479761	3800462	3800498
ENSE00003520585	3801924	3802100
ENSE00003539992	3800288	3800329
ENSE00003546037	3803108	3803206
ENSE00003562933	3800743	3800865
ENSE00003590227	3801254	3801388
ENSE00003643614	3804569	3804680
ENSE00003654862	3800971	3801093
ENSE00003657182	3798412	3798463
ENSE00003657435	3802281	3802376
ENSE00003661786	3803404	3803537
ENSE00003669692	3801722	3801802
ENSE00003683245	3802910	3802972

Expression profiles

Bgee: expression breadth ubiquitous, 279 present calls, max score 97.71.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 56.6886 / max 551.6646, expressed in 1815 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
183226	34.1152	1741
183223	10.7850	1693
183229	3.3176	1145
183227	1.6258	917
183221	1.5281	465
183225	1.5155	839
183228	1.2083	766
208977	1.1980	814
183224	1.0732	655
183222	0.2117	90

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	97.71	gold quality
right lung	UBERON:0002167	97.56	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.37	gold quality
cerebellar hemisphere	UBERON:0002245	97.25	gold quality
cerebellar cortex	UBERON:0002129	97.21	gold quality
cerebellum	UBERON:0002037	96.79	gold quality
mucosa of stomach	UBERON:0001199	96.69	gold quality
endometrium epithelium	UBERON:0004811	96.67	gold quality
upper lobe of left lung	UBERON:0008952	96.66	gold quality
upper lobe of lung	UBERON:0008948	96.55	gold quality
oocyte	CL:0000023	96.36	gold quality
stromal cell of endometrium	CL:0002255	95.35	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.32	gold quality
secondary oocyte	CL:0000655	95.11	gold quality
lymph node	UBERON:0000029	95.05	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.01	gold quality
lower esophagus	UBERON:0013473	94.96	gold quality
metanephros cortex	UBERON:0010533	94.92	gold quality
adenohypophysis	UBERON:0002196	94.81	gold quality
paraflocculus	UBERON:0005351	94.64	gold quality
pituitary gland	UBERON:0000007	94.62	gold quality
body of uterus	UBERON:0009853	94.62	gold quality
spleen	UBERON:0002106	94.39	gold quality
ventricular zone	UBERON:0003053	94.39	gold quality
muscle layer of sigmoid colon	UBERON:0035805	94.16	gold quality
right ovary	UBERON:0002118	94.09	gold quality
left uterine tube	UBERON:0001303	94.07	gold quality
cerebellar vermis	UBERON:0004720	93.83	gold quality
left lobe of thyroid gland	UBERON:0001120	93.78	gold quality
thymus	UBERON:0002370	93.58	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-36552	yes	293.93
E-HCAD-4	yes	57.73
E-CURD-122	yes	8.46
E-ANND-3	yes	5.41
E-CURD-120	no	6.80

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXM1, MYBL2, MYC, NFKB, NFYB, SP1, SP3, TP53

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 18.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• nuclear localization and serine 146 integrity required for induction of mitosis (PMID:12107172)
• pEg3 kinase is able to specifically phosphorylate CDC25B in vitro. One phosphorylation site was identified and corresponded to serine 323 (PMID:12400006)
• we demonstrate that phosphorylation of CDC25B by protein kinase CK2 increases the catalytic activity of the phosphatase in vitro as well as in vivo.CDC25B interacts with CK2, and this interaction, mediated by the CK2beta regulatory subunit (PMID:12527891)
• upregulation of Cdc25B in human prostate cancer and its interplay with androgen receptor may contribute to prostate cancer development (PMID:12569365)
• Data show that FHL3 (human four-and-a-half LIM-only protein 3) interacts with human phosphatase CDC25B in the cell nucleus. (PMID:12681290)
• Cdc25B may play important roles in the development and progression of endometrioid endometrial carcinoma and clear cell carcinoma and uterine pappillary serous carcinoma by different mechanism. (PMID:14559803)
• cdc25B plays a role in the early phase of thyroid lymphoma possibly including the malignant transformation from chronic thyroiditis (PMID:14767575)
• Identification of a nuclear export signal in CDC25B. (PMID:15003534)
• Phosphorylation of CDC25B by AURA at the centrosome contributes to the G2-M transition. (PMID:15128871)
• 14-3-3 subtypes can control the subcellular localization of CDC25B by binding to a specific site. (PMID:15173315)
• Cdc25B localisation and nuclear export changes during the cell cycle and in response to stress (PMID:15456846)
• Results suggest that cdc25B is important especially in the early phase of breast carcinoma progression. (PMID:15550849)
• These results support a model in which pEg3 contributes to the control of progression through mitosis by phosphorylation of the CDC25 phosphatases. (PMID:15908796)
• Aurora-A-mediated phosphorylation of CDC25B at the centrosome is an important step contributing to the earliest events inducing mitosis, upstream of CDK1-cyclin B1 activation (PMID:16082213)
• MAPKAP kinase-2 phosphorylates CDC25B on multiple sites including S169, S323, S353 and S375, while p38SAPK phosphorylates CDC25B on S249. (PMID:16861915)
• Results show under normal cell cycle conditions and in the absence of DNA damage, CDC25B is constitutively phosphorylated by CHK1 during interphase and thus prevents the premature initiation of mitosis. (PMID:17003105)
• Caulibugulone inhibition of cellular Cdc25A and B phosphatases occurred through at least two different mechanisms, leading to pronounced cell cycle arrest. (PMID:17018577)
• Chk1 functions to coordinate mitotic events through regulation of Cdc25B (PMID:17106257)
• The expression of CDC25B in different cellular compartments of human spermatozoa suggests that there are diverse noncell-cycle-related functions of CDC25B in terminally differentiated human germ cells. (PMID:17336969)
• p38 regulates the timing of mitotic entry via modulation of Cdc25B activity under normal nonstress conditions (PMID:17548358)
• Cdc25B, but not Cdc25C, is capable of inhibiting cellular proliferation in a manner dependent upon its catalytic activity (PMID:17591782)
• CDC25B splice variants have differential mitotic stabilities, a feature that is likely to have major consequences on the local control of cyclin-dependent kinase-cyclin activities during mitotic progression. (PMID:17599046)
• CDC25B might play an important role in the angiogenic process and in determining the prognosis of patients with non-small cell lung carcinoma (PMID:17651784)
• Abnormal expression of CDC25B in human tumors may have a critical role in centrosome amplification and genomic instability. (PMID:18089784)
• Inhibition of CDC25B by siRNA results in accumulation of cells in G2 phase with two separated centrosomes. (PMID:18235220)
• CDC25B mRNA was overexpressed in 64 of the 73 esophageal squamous cell carcinoma cases evaluated. (PMID:18559558)
• This work suggests that the expression level of CDC25B might be a potential key parameter of the cellular response to cancer therapy. (PMID:18635965)
• Importance of a novel JNK/p38-Cdc25B axis for a nongenotoxic stress-induced cell cycle checkpoint. (PMID:19638579)
• MAPK pathway activation delays G2/M progression by destabilizing Cdc25B (PMID:19801682)
• Adventitious arsenate reductase activity of the catalytic domain of the human Cdc25B phosphatases. (PMID:20025242)
• A moderate and unscheduled increase in CDC25B level, as observed in a number of human tumours, is sufficient to overcome the S-phase checkpoint efficiency thus leading to replicative stress and genomic instability. (PMID:20128929)
• A new mechanism of CDC25B regulation in response to stress. (PMID:20176018)
• CDC25B a minor role in the pathogenesis and/or progression of vulvar squamous cell carcinomas. (PMID:20500813)
• The mitotic phosphorylation of Ser(321) acts to maintain full activation of Cdc25B by disrupting 14-3-3 binding to Ser(323) and enhancing the dephosphorylation of Ser(323) to block 14-3-3 binding to this site. (PMID:20801879)
• Cdc14A phosphatase prevents premature activation of Cdk1 regulating Cdc25A and Cdc25B at the entry into mitosis. (PMID:20956543)
• CDC25B forms a close association with Ctn-2 proteins at the centrosome. (PMID:21091437)
• Deletion and mutation analyses of the Cdc25B promoter revealed that downregulation by p53 is dependent on the presence of functional Sp1/Sp3 and NF-Y binding sites (PMID:21242964)
• Our findings reveal the existence of a previously unrecognized CDC25B isoform that operates specifically in the nucleus to reinitiate G2/M transition after DNA damage (PMID:21363925)
• Ser169 phosphorylation can disrupt 14-3-3 binding to Ser151 activating Cdc25B3, providing a mechanism for regulating Cdc25B3 activation without dephosphorylation of the 14-3-3 binding sites. (PMID:21558810)
• there are 13 sites phosphorylated by PLK1 in CDC25B.This study illustrates the complexity of the phosphorylation pattern and of the subsequent regulation of CDC25B activity. (PMID:21640712)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cdc25b	ENSMUSG00000027330
rattus_norvegicus	Cdc25b	ENSRNOG00000021248
caenorhabditis_elegans		WBGENE00000387
caenorhabditis_elegans		WBGENE00000388

Paralogs (2): CDC25C (ENSG00000158402), CDC25A (ENSG00000164045)

Protein

Protein identifiers

M-phase inducer phosphatase 2 — P30305 (reviewed: P30305)

Alternative names: Dual specificity phosphatase Cdc25B

All UniProt accessions (3): P30305, B4DIG0, G8JLH2

UniProt curated annotations — full annotation on UniProt →

Function. Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Directly dephosphorylates CDK1 and stimulates its kinase activity. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. The three isoforms seem to have a different level of activity.

Subunit / interactions. Interacts with MAPK14 and 14-3-3 proteins.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Spindle pole.

Post-translational modifications. Phosphorylated by BRSK1 in vitro. Phosphorylated by CHEK1, which inhibits the activity of this protein. Phosphorylation at Ser-353 by AURKA might locally participate in the control of the onset of mitosis. Phosphorylation by MELK at Ser-169 promotes localization to the centrosome and the spindle poles during mitosis. Phosphorylation at Ser-323 and Ser-375 by MAPK14 is required for binding to 14-3-3 proteins.

Activity regulation. Stimulated by B-type cyclins.

Similarity. Belongs to the MPI phosphatase family.

Isoforms (4)

UniProt ID	Names	Canonical?
P30305-1	3, CDC25B3	yes
P30305-2	1, CDC25B1
P30305-3	2, CDC25B2
P30305-4	4

RefSeq proteins (10): NP_001274445, NP_001274446, NP_001274447, NP_001274448, NP_001274449, NP_001274451, NP_001274453, NP_004349, NP_068658, NP_068659* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000751	MPI_Phosphatase	Family
IPR001763	Rhodanese-like_dom	Domain
IPR036873	Rhodanese-like_dom_sf	Homologous_superfamily

Pfam: PF00581, PF06617

Enzyme classification (BRENDA):

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (38 total): modified residue 8, helix 8, strand 6, region of interest 4, splice variant 3, turn 2, compositionally biased region 2, chain 1, domain 1, sequence variant 1, sequence conflict 1, active site 1

Structure

Experimental structures (PDB)

19 structures.

PDB	Method	Resolution (Å)
9T09	X-RAY DIFFRACTION	1.34
4WH9	X-RAY DIFFRACTION	1.5
2A2K	X-RAY DIFFRACTION	1.52
2IFV	X-RAY DIFFRACTION	1.6
4WH7	X-RAY DIFFRACTION	1.62
1YMD	X-RAY DIFFRACTION	1.7
1YMK	X-RAY DIFFRACTION	1.7
1YML	X-RAY DIFFRACTION	1.7
3FQT	X-RAY DIFFRACTION	1.8
3FQU	X-RAY DIFFRACTION	1.8
1QB0	X-RAY DIFFRACTION	1.91
1CWS	X-RAY DIFFRACTION	2
1YM9	X-RAY DIFFRACTION	2
1YS0	X-RAY DIFFRACTION	2
2IFD	X-RAY DIFFRACTION	2
9T0A	X-RAY DIFFRACTION	2.04
1CWR	X-RAY DIFFRACTION	2.1
1CWT	X-RAY DIFFRACTION	2.3
2UZQ	X-RAY DIFFRACTION	2.38

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P30305-F1	64.43	0.30

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 487

Post-translational modifications (8): 169, 249, 323, 353, 375, 470, 563, 42

Function

Pathways and Gene Ontology

Reactome pathways

16 pathways

ID	Pathway
R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition
R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry
R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models
R-HSA-9825892	Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
R-HSA-1266738	Developmental Biology
R-HSA-1640170	Cell Cycle
R-HSA-1643685	Disease
R-HSA-453274	Mitotic G2-G2/M phases
R-HSA-69242	S Phase
R-HSA-69275	G2/M Transition
R-HSA-69278	Cell Cycle, Mitotic
R-HSA-8863678	Neurodegenerative Diseases
R-HSA-9645723	Diseases of programmed cell death
R-HSA-9730414	MITF-M-regulated melanocyte development
R-HSA-9734009	Defective Intrinsic Pathway for Apoptosis
R-HSA-9856651	MITF-M-dependent gene expression

MSigDB gene sets: 379 (showing top): SA_G2_AND_M_PHASES, WU_APOPTOSIS_BY_CDKN1A_VIA_TP53, MODULE_52, GOBP_POSITIVE_REGULATION_OF_REPRODUCTIVE_PROCESS, HORIUCHI_WTAP_TARGETS_DN, KEGG_MAPK_SIGNALING_PATHWAY, BIOCARTA_SRCRPTP_PATHWAY, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, DITTMER_PTHLH_TARGETS_UP, GOBP_OOGENESIS, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN, GOBP_REGULATION_OF_MEIOTIC_CELL_CYCLE, CAGCTG_AP4_Q5

GO Biological Process (13): G2/M transition of mitotic cell cycle (GO:0000086), mitotic cell cycle (GO:0000278), oocyte maturation (GO:0001556), protein phosphorylation (GO:0006468), female meiosis I (GO:0007144), positive regulation of cell population proliferation (GO:0008284), positive regulation of G2/M transition of mitotic cell cycle (GO:0010971), positive regulation of cytokinesis (GO:0032467), positive regulation of mitotic cell cycle (GO:0045931), cell division (GO:0051301), positive regulation of G2/MI transition of meiotic cell cycle (GO:0110032), protein dephosphorylation (GO:0006470), positive regulation of cell cycle G2/M phase transition (GO:1902751)

GO Molecular Function (5): phosphoprotein phosphatase activity (GO:0004721), protein tyrosine phosphatase activity (GO:0004725), protein kinase binding (GO:0019901), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (7): spindle pole (GO:0000922), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), centrosome (GO:0005813), cytosol (GO:0005829), cytoskeleton (GO:0005856)

Reactome top-level categories

Rollup of top-12 pathways:

Category	Pathways
Cell Cycle, Mitotic	2
G2/M Transition	1
S Phase	1
Neurodegenerative Diseases	1
MITF-M-dependent gene expression	1
Mitotic G2-G2/M phases	1
Cell Cycle	1
Defective Intrinsic Pathway for Apoptosis	1
Disease	1
Developmental Biology	1
Diseases of programmed cell death	1
MITF-M-regulated melanocyte development	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
mitotic cell cycle	2
cell cycle G2/M phase transition	2
protein modification process	2
positive regulation of cell cycle G2/M phase transition	2
mitotic cell cycle phase transition	1
cell cycle	1
mitotic nuclear division	1
developmental process involved in reproduction	1
cell maturation	1
oocyte development	1
phosphorylation	1
meiosis I	1
female meiotic nuclear division	1
female gamete generation	1
meiotic cell cycle	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
G2/M transition of mitotic cell cycle	1
regulation of G2/M transition of mitotic cell cycle	1
positive regulation of mitotic cell cycle phase transition	1
cytokinesis	1
regulation of cytokinesis	1
positive regulation of cell division	1
positive regulation of cell cycle process	1
regulation of mitotic cell cycle	1
positive regulation of cell cycle	1
cellular process	1
G2/MI transition of meiotic cell cycle	1
regulation of G2/MI transition of meiotic cell cycle	1
positive regulation of meiotic cell cycle phase transition	1
dephosphorylation	1
positive regulation of cell cycle phase transition	1
regulation of cell cycle G2/M phase transition	1
phosphatase activity	1
catalytic activity, acting on a protein	1
phosphoprotein phosphatase activity	1
kinase binding	1
binding	1

Protein interactions and networks

STRING

1708 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDC25B	CDK2	P24941	968
CDC25B	CCNA2	P20248	946
CDC25B	CCNA1	P78396	942
CDC25B	CDK1	P06493	933
CDC25B	CCNB1	P14635	838
CDC25B	WEE1	P30291	811
CDC25B	YWHAB	P31946	801
CDC25B	FOXM1	Q08050	735
CDC25B	CDC20	Q12834	716
CDC25B	YWHAE	P29360	715
CDC25B	PLK1	P53350	707
CDC25B	CDC45	O75419	703
CDC25B	CCND1	P24385	701
CDC25B	CENPF	P49454	694
CDC25B	CHEK1	O14757	659
CDC25B	CDK4	P11802	659

IntAct

117 interactions, top by confidence:

A	B	Type	Score
CDC25B	YWHAZ	psi-mi:“MI:0914”(association)	0.940
CDC25B	YWHAZ	psi-mi:“MI:0915”(physical association)	0.940
YWHAZ	CDC25B	psi-mi:“MI:0915”(physical association)	0.940
YWHAZ	CDC25B	psi-mi:“MI:0914”(association)	0.940
YWHAZ	CDC25B	psi-mi:“MI:0407”(direct interaction)	0.940
YWHAB	CDC25B	psi-mi:“MI:0915”(physical association)	0.910
CDC25B	YWHAB	psi-mi:“MI:0915”(physical association)	0.910
YWHAB	CDC25B	psi-mi:“MI:0914”(association)	0.910
CDC25B	YWHAB	psi-mi:“MI:0914”(association)	0.910
YWHAH	CDC25B	psi-mi:“MI:0915”(physical association)	0.870
CDC25B	YWHAH	psi-mi:“MI:0915”(physical association)	0.870
CDC25B	YWHAH	psi-mi:“MI:0914”(association)	0.870
YWHAG	CDC25B	psi-mi:“MI:0914”(association)	0.790
CDC25B	YWHAE	psi-mi:“MI:0915”(physical association)	0.760
YWHAE	CDC25B	psi-mi:“MI:0915”(physical association)	0.760
SFN	CDC25B	psi-mi:“MI:0915”(physical association)	0.690
SFN	CDC25B	psi-mi:“MI:0914”(association)	0.690
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
CDC25B	PSME3	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (211): CDC25B (Affinity Capture-MS), CDC25B (Affinity Capture-MS), CDC25B (Affinity Capture-MS), CDC25B (Affinity Capture-MS), CDC25B (Affinity Capture-MS), CDC25B (Affinity Capture-MS), CDC25B (Proximity Label-MS), CDC25B (Affinity Capture-MS), CDC5L (Affinity Capture-MS), CENPB (Affinity Capture-MS), EIF4B (Affinity Capture-MS), YWHAB (Affinity Capture-MS), YWHAG (Affinity Capture-MS), YWHAH (Affinity Capture-MS), YWHAZ (Affinity Capture-MS)

ESM2 similar proteins: A0A1D5PRR9, A0JPN4, A4PES0, A4QNA8, B5DFG1, D2HHP1, D4A7V9, E1BTE1, E2RSS3, O57473, O88622, O88866, P0C1S8, P30305, P33279, P47810, P47817, P48966, P54350, Q08D35, Q1LX51, Q2KIP2, Q3TLR7, Q4V837, Q5RHD1, Q5RHI5, Q5ZJW8, Q63802, Q66JT0, Q6DFE0, Q6NVF4, Q6P1H6, Q6P1W0, Q6Z829, Q7TP65, Q8AYK6, Q8BGE5, Q8BMI4, Q8C0Q4, Q8IVT5

Diamond homologs: A5D7P0, A7MBD1, O44552, O44628, P06652, P20483, P23748, P30303, P30304, P30305, P30306, P30307, P30308, P30309, P30310, P30311, P30634, P48964, P48965, P48966, P48967, P48968, Q03019, Q29029, Q54QM6, Q8WZK3, P54510, Q8GY31

SIGNOR signaling

36 interactions.

A	Effect	B	Mechanism
BRSK1	“down-regulates activity”	CDC25B	phosphorylation
p38	“down-regulates activity”	CDC25B	phosphorylation
PCSK7	down-regulates	CDC25B	phosphorylation
BRSK1	down-regulates	CDC25B	phosphorylation
ROBO	down-regulates	CDC25B	phosphorylation
MELK	up-regulates	CDC25B	phosphorylation
AURKA	up-regulates	CDC25B	phosphorylation
CHEK1	“down-regulates activity”	CDC25B	phosphorylation
CDK1	up-regulates	CDC25B	phosphorylation
RPS6KA1	up-regulates	CDC25B	phosphorylation
CyclinB/CDK1	up-regulates	CDC25B	phosphorylation
CDC25B	up-regulates	CyclinB/CDK1	dephosphorylation
RPS6K	up-regulates	CDC25B	phosphorylation
MELK	“down-regulates activity”	CDC25B	phosphorylation
p38	“down-regulates quantity by destabilization”	CDC25B	phosphorylation
MAPK8	“down-regulates quantity by destabilization”	CDC25B	phosphorylation
SCF-betaTRCP	“down-regulates quantity by destabilization”	CDC25B	ubiquitination
CDC14A	“down-regulates activity”	CDC25B	dephosphorylation
CDC25B	“up-regulates activity”	CDK1	dephosphorylation
CDC25B	“up-regulates activity”	CDK2	dephosphorylation
MARK3	“up-regulates activity”	CDC25B	phosphorylation
MARK3	“down-regulates activity”	CDC25B	phosphorylation
PRKACA	“up-regulates activity”	CDC25B	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 90 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	83.3×	2e-10
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	73.5×	2e-10
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	73.5×	2e-10
Activation of BH3-only proteins	7	54.3×	2e-09
RHO GTPases activate PKNs	7	34.7×	5e-08
Intrinsic Pathway for Apoptosis	7	32.0×	8e-08
FOXO-mediated transcription	5	26.2×	2e-05
SARS-CoV-1-host interactions	7	19.2×	2e-06

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	6	26.5×	5e-05
intracellular protein localization	8	10.1×	2e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

120 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	84
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2447 predictions. Top by Δscore:

Variant	Effect	Δscore
20:3797600:C:A	acceptor_gain	1.0000
20:3797601:G:A	acceptor_gain	1.0000
20:3797748:AGGTG:A	donor_loss	1.0000
20:3797749:GGTGA:G	donor_loss	1.0000
20:3797750:GTG:G	donor_loss	1.0000
20:3797751:T:A	donor_loss	1.0000
20:3800330:G:GG	donor_gain	1.0000
20:3800460:A:AG	acceptor_gain	1.0000
20:3800461:G:GG	acceptor_gain	1.0000
20:3800461:GC:G	acceptor_gain	1.0000
20:3800851:G:GT	donor_gain	1.0000
20:3800851:G:T	donor_gain	1.0000
20:3800860:GAGAA:G	donor_gain	1.0000
20:3800861:A:T	donor_gain	1.0000
20:3800862:GAAT:G	donor_gain	1.0000
20:3800877:G:GT	donor_gain	1.0000
20:3800878:A:T	donor_gain	1.0000
20:3801052:G:T	donor_gain	1.0000
20:3801245:T:G	acceptor_gain	1.0000
20:3801247:T:TA	acceptor_gain	1.0000
20:3801248:G:A	acceptor_gain	1.0000
20:3801252:A:AG	acceptor_gain	1.0000
20:3801253:G:GA	acceptor_gain	1.0000
20:3801253:GT:G	acceptor_gain	1.0000
20:3801253:GTGT:G	acceptor_gain	1.0000
20:3801385:AAAG:A	donor_loss	1.0000
20:3801386:AAG:A	donor_loss	1.0000
20:3801387:AGG:A	donor_loss	1.0000
20:3801389:GTAA:G	donor_loss	1.0000
20:3801390:T:G	donor_loss	1.0000

AlphaMissense

3818 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:3803172:G:C	R441T	1.000
20:3803172:G:T	R441I	1.000
20:3803173:A:C	R441S	1.000
20:3803173:A:T	R441S	1.000
20:3803185:A:C	E445D	1.000
20:3803185:A:T	E445D	1.000
20:3803196:G:A	G449E	1.000
20:3803512:T:C	F489L	1.000
20:3803514:C:A	F489L	1.000
20:3803514:C:G	F489L	1.000
20:3804583:G:C	R502T	1.000
20:3804583:G:T	R502M	1.000
20:3804584:G:C	R502S	1.000
20:3804584:G:T	R502S	1.000
20:3804595:G:C	R506P	1.000
20:3802950:T:C	L412P	0.999
20:3802959:T:A	I415N	0.999
20:3803165:G:C	D439H	0.999
20:3803166:A:C	D439A	0.999
20:3803166:A:G	D439G	0.999
20:3803166:A:T	D439V	0.999
20:3803168:T:C	C440R	0.999
20:3803169:G:A	C440Y	0.999
20:3803170:C:G	C440W	0.999
20:3803171:A:G	R441G	0.999
20:3803184:A:T	E445V	0.999
20:3803195:G:T	G449W	0.999
20:3803196:G:T	G449V	0.999
20:3803198:C:G	H450D	0.999
20:3803202:T:A	I451N	0.999

dbSNP variants (sampled 300 via entrez): RS1000143436 (20:3790557 C>T), RS1000273837 (20:3797420 G>GTCA), RS1000546648 (20:3796185 C>T), RS1000681217 (20:3796566 C>G,T), RS1000819813 (20:3803699 G>A,T), RS1001062786 (20:3795812 C>T), RS1001319577 (20:3792993 G>A), RS1001427511 (20:3805006 GA>G), RS1001582524 (20:3792675 C>T), RS1001795050 (20:3805179 G>A,T), RS1002187102 (20:3791162 A>G), RS1002361848 (20:3797806 T>C), RS1002378628 (20:3792636 G>A), RS1002594297 (20:3805936 A>G), RS1002727750 (20:3791435 C>T)

Disease associations

OMIM: gene MIM:116949 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST003075_23	Cognitive decline rate in late mild cognitive impairment	6.000000e-07
GCST004634_12	Basophil percentage of granulocytes	6.000000e-09
GCST012256_13	SAPHO syndrome	1.000000e-07
GCST90002390_665	Mean corpuscular hemoglobin	1.000000e-22
GCST90002392_81	Mean corpuscular volume	7.000000e-18
GCST90002396_50	Mean reticulocyte volume	6.000000e-15
GCST90002397_446	Mean spheric corpuscular volume	5.000000e-16

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007710	cognitive decline measurement
EFO:0007995	basophil percentage of granulocytes
EFO:0004527	mean corpuscular hemoglobin
EFO:0010701	mean reticulocyte volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4804 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 27,336 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL590	MENADIONE	4	21,034
CHEMBL292009	BUPARVAQUONE	2	8
CHEMBL85943	SODIUM TUNGSTATE	2
CHEMBL295316	PLUMBAGIN	1	6,294

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

46 measured of 115 human assays (120 total across all organisms); most potent 46 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
6-Amino-4-(3-ethoxy-4-hydroxy-phenyl)-3-phenyl-1,4-dihydro-pyrano[2,3-c]pyrazole	EC50	0.00738 nM
1-Ethyl-6-methyl-3-thiophen-2-yl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione	IC50	72.2 nM
1,8-bis(azanyl)-3,6-dipyrrolidin-1-yl-2,7-naphthyridine-4-carbonitrile	IC50	3170 nM
(5-oxidanidyl-4-thiophen-2-ylcarbonyl-1,2,5-oxadiazol-5-ium-3-yl)-thiophen-2-yl-methanone	IC50	3490 nM
2-[(5-amino-1H-1,2,4-triazol-3-yl)sulfanyl]-N-[3-cyano-7,7-dimethyl-5-[(E)-2-(5-methylfuran-2-yl)ethenyl]-6H-1-benzothiophen-2-yl]acetamide	EC50	6380 nM
MLS000071484	IC50	6410 nM
MLS000082957	IC50	10400 nM
MLS000050867	IC50	11400 nM
3-amino-N-(5-propylsulfanyl-1,3,4-thiadiazol-2-yl)-6-thiophen-2-ylthieno[2,3-b]pyridine-2-carboxamide	IC50	12400 nM
(5Z)-5-(5-bromo-2-methoxybenzylidene)-2-(2-furyl)[1,3]thiazolo[3,2-b][1,2,4]triazol-6(5H)-one	IC50	12800 nM
MLS000085603	IC50	14200 nM
MLS000106874	IC50	14300 nM
8-(cyclohexoxycarbonyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid	IC50	14500 nM
2-(4-ethoxyphenyl)-5-[1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinyl]-6-pyrazolo[1,5-a]pyrimidinecarboxylic acid	IC50	15000 nM
8-carbethoxy-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid	IC50	15800 nM
2-(2-furanyl)-4-quinolinecarboxylic acid [2-[4-amino-1-methyl-3-(2-methylpropyl)-2,6-dioxo-5-pyrimidinyl]-2-oxoethyl] ester	IC50	16800 nM
MLS000079944	IC50	17000 nM
2-(7-Ethyl-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-ylsulfanyl)-N-(6-methoxy-benzothiazol-2-yl)-acetamide	IC50	18200 nM
1,2-Dione-Based Compound, 8	IC50	18400 nM
3-hydroxy-2-phenyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one	IC50	20100 nM
MLS000093276	IC50	22700 nM
(Z)-7-[(1R,2S)-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-keto-cyclopent-3-en-1-yl]hept-5-enoic acid	IC50	23300 nM
MLS000054842	IC50	23500 nM
MLS000091355	IC50	24900 nM
5-chloranyl-3-[2-[4-(2,3-dimethylphenyl)piperazin-1-yl]-2-oxidanylidene-ethyl]-1H-indole-2-carboxylic acid	IC50	25800 nM
2-amino-1-(3-methoxypropyl)-N-(3-methylbutyl)-3-pyrrolo[3,2-b]quinoxalinecarboxamide	IC50	26200 nM
2-(1,5-dimethyl-3-oxidanylidene-2-phenyl-pyrazol-4-yl)iminoindene-1,3-dione	IC50	26200 nM
2-(4-methoxyphenyl)-5-[1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinyl]-6-pyrazolo[1,5-a]pyrimidinecarboxylic acid	IC50	26900 nM
9-cis-retinoic acid (9cRA)	IC50	27100 nM
MLS000106837	IC50	30200 nM
6-chloranyl-N-[2-(cyclohexen-1-yl)ethyl]-5-methyl-7-oxidanylidene-1H-pyrazolo[1,5-a]pyrimidine-3-carboxamide	IC50	31100 nM
MLS000050353	EC50	33300 nM
MLS000094302	IC50	35900 nM
5-({4-[2-cyano-2-(4-fluorophenyl)vinyl]-2-ethoxyphenoxy}methyl)-2-furoic acid	IC50	36100 nM
2,3-bis(2-furanyl)-N-phenyl-6-quinoxalinecarboxamide	EC50	36500 nM
5-oxidanylidene-N3-(oxolan-2-ylmethyl)-N8-pentyl-1-sulfanylidene-4H-[1,3]thiazolo[3,4-a]quinazoline-3,8-dicarboxamide	IC50	36700 nM
MLS000081820	IC50	39000 nM
6,7-dimethyl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-4-carboxylic acid	IC50	40400 nM
6-hydroxy-4-phenyl-3,4-dihydro-2H-1-benzopyran-2-one	IC50	44200 nM
MLS000095236	IC50	45800 nM
MLS000096457	IC50	46600 nM
MLS000038842	IC50	47700 nM
1-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]-2-[(5,7-dimethyl-[1,2,4]triazolo[4,3-a]pyrimidin-3-yl)thio]ethanone	IC50	48800 nM
2-({[3-{[(3-methylphenyl)amino]carbonyl}-4-(1-piperidinyl)phenyl]amino}carbonyl)cyclohexanecarboxylic acid	IC50	49200 nM
3-(2,5-dimethyl-1-pyrrolyl)benzoic acid	EC50	49500 nM
1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione	KI	171000 nM	US-9284299: Substituted 1H-indazol-1-ol analogs as inhibitors of beta catenin/Tcf protein-protein interactions

ChEMBL bioactivities

393 potent at pChembl≥5 of 647 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.28	IC50	53	nM	CHEMBL5271462
7.28	IC50	53	nM	CHEMBL5288122
7.16	IC50	70	nM	ADOCIAQUINONE B
7.10	Ki	80	nM	CHEMBL1481974
7.10	IC50	80	nM	ADOCIAQUINONE B
7.02	Ki	95	nM	CHEMBL337173
7.00	IC50	100	nM	CHEMBL1481974
7.00	IC50	100	nM	CHEMBL429095
6.96	IC50	110	nM	ADOCIAQUINONE B
6.92	IC50	120	nM	CHEMBL200117
6.92	IC50	120	nM	CHEMBL1095726
6.90	IC50	125	nM	CHEMBL429095
6.80	IC50	160	nM	CHEMBL1097720
6.77	IC50	170	nM	CHEMBL1098494
6.72	IC50	190	nM	CHEMBL5423941
6.70	IC50	200	nM	CHEMBL557129
6.68	IC50	210	nM	SODIUM ORTHOVANAD
6.68	IC50	210	nM	CHEMBL557673
6.68	IC50	210	nM	CHEMBL337173
6.64	IC50	230	nM	CHEMBL1099219
6.62	IC50	240	nM	CHEMBL1097552
6.60	IC50	250	nM	CHEMBL4452484
6.60	IC50	250	nM	CHEMBL1098495
6.60	IC50	250	nM	CHEMBL1765351
6.57	IC50	270	nM	CHEMBL50620
6.52	IC50	300	nM	CHEMBL131199
6.51	IC50	310	nM	CHEMBL1097794
6.50	IC50	320	nM	CHEMBL4475724
6.50	IC50	320	nM	CHEMBL1094563
6.47	IC50	340	nM	CHEMBL1098821
6.43	Ki	369	nM	CHEMBL2000194
6.43	IC50	370	nM	CHEMBL57013
6.42	IC50	380	nM	CHEMBL4445615
6.40	IC50	400	nM	SHIKONIN
6.40	IC50	400	nM	CHEMBL511236
6.40	IC50	400	nM	CHEMBL1095107
6.39	IC50	410	nM	CHEMBL1098791
6.37	Ki	430	nM	CHEMBL86333
6.37	IC50	430	nM	CHEMBL340653
6.35	IC50	450	nM	CHEMBL1099201
6.35	IC50	450	nM	CHEMBL131141
6.31	IC50	490	nM	CHEMBL4450252
6.31	IC50	490	nM	CHEMBL1098792
6.30	IC50	500	nM	CHEMBL1095106
6.29	IC50	510	nM	CHEMBL339439
6.28	IC50	520	nM	CHEMBL1097152
6.27	IC50	540	nM	CHEMBL1097486
6.27	IC50	540	nM	CHEMBL1095854
6.23	IC50	590	nM	CHEMBL448099
6.22	IC50	600	nM	CHEMBL2000194

PubChem BioAssay actives

364 with measured affinity, of 1052 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
5-[2-(dimethylamino)ethylamino]-2-methyl-1,3-benzothiazole-4,7-dione	1942249: Inhibition of recombinant CDC25B (unknown origin)	ic50	0.0530	uM
2-(2,5-difluorophenyl)-6-[2-(dimethylamino)ethylamino]-1,3-benzoxazole-4,7-dione	1942249: Inhibition of recombinant CDC25B (unknown origin)	ic50	0.0530	uM
(1S)-1-methyl-7,7-dioxo-18-oxa-7lambda6-thia-10-azahexacyclo[15.6.1.02,15.04,13.06,11.020,24]tetracosa-2(15),3,6(11),13,17(24),19-hexaene-5,12,16-trione	387758: Inhibition of human recombinant CDC25B	ic50	0.0700	uM
3-(3,4,5-trihydroxy-6-oxoxanthen-9-yl)propanoic acid	673295: Competitive inhibition of recombinant phosphatase activity of Cdc25B catalytic domain expressed in Escherichia coli BL21(DE3) using OMFP as substrate by Lineweaver-Burk plot analysis	ki	0.0800	uM
6-chloro-7-(2-morpholin-4-ylethylamino)quinoline-5,8-dione	593356: Inhibition of human Cdc25B	ki	0.0950	uM
2,3-bis(2-hydroxyethylsulfanyl)naphthalene-1,4-dione	307127: Inhibition of GST tagged Cdc25B	ic50	0.1000	uM
2-[4-[7-(4-tetradecylbenzoyl)cyclopenta[d]oxazin-4-yl]phenoxy]acetic acid	259932: Inhibitory activity against cdc25B phosphatase	ic50	0.1200	uM
3-[(3-octadecanoyl-1H-pyrazole-5-carbonyl)amino]thiophene-2-carboxylic acid	480745: Inhibition of CDC25B	ic50	0.1200	uM
2-[(3-octadecanoyl-1H-pyrazole-5-carbonyl)amino]benzoic acid	480745: Inhibition of CDC25B	ic50	0.1600	uM
5-(4-chlorophenyl)-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.1700	uM
6-chloro-7-[1-[1-[4-(hydroxymethyl)phenyl]triazol-4-yl]ethylamino]quinoline-5,8-dione	2009522: Inhibition of full-length recombinant human CDC25B using OMFP as substrate incubated for 5 to 8 mins by fluorescence based assay	ic50	0.1900	uM
N-(1-benzyl-3-cyanopyrrolo[3,2-b]quinoxalin-2-yl)benzenesulfonamide	432341: Inhibition of GST-fused Cdc25B	ic50	0.2000	uM
N-(1-benzylpyrrolo[3,2-b]quinoxalin-2-yl)benzenesulfonamide	432341: Inhibition of GST-fused Cdc25B	ic50	0.2100	uM
3-octadecanoyl-5-phenyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.2300	uM
5-(3-chlorophenyl)-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.2400	uM
2,3-bis(methylsulfanyl)naphthalene-1,4-dione	1517765: Inhibition of recombinant Cdc25B (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay	ic50	0.2500	uM
5-(2-bromophenyl)-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.2500	uM
5-[2-(dimethylamino)ethylamino]-2,6-dimethyl-1,3-benzothiazole-4,7-dione	593356: Inhibition of human Cdc25B	ic50	0.2500	uM
4-ethoxynaphthalene-1,2-dione	417086: Inhibition of histidine-tagged human recombinant Cdc25B catalytic domain expressed in Escherichia coli	ic50	0.2700	uM
6-chloro-7-(2,3-dihydro-1H-inden-1-ylamino)quinoline-5,8-dione	51883: Inhibitory activity against recombinant human cell division cycle 25B	ic50	0.3000	uM
5-naphthalen-1-yl-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.3100	uM
2-[(5Z)-5-[[6-[(4-bromophenyl)methoxy]naphthalen-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-(1H-indol-3-yl)propanoic acid	1551281: Inhibition of human recombinant GST-tagged CDC25B expressed in Escherichia coli BL21 (DE3) using pNPP as substrate measured for 2 mins by colorimetric analysis	ic50	0.3200	uM
3-octadecanoyl-5-[2-(trifluoromethyl)phenyl]-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.3200	uM
methyl 3-(3-octadecanoyl-4,6-dioxo-1H-pyrrolo[3,4-d]pyrazol-5-yl)thiophene-2-carboxylate	480745: Inhibition of CDC25B	ic50	0.3400	uM
methyl 5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methylpyridine-2-carboxylate	51883: Inhibitory activity against recombinant human cell division cycle 25B	ic50	0.3700	uM
2-[(5Z)-5-[[6-[(4-fluorophenyl)methoxy]naphthalen-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-(1H-indol-3-yl)propanoic acid	1551281: Inhibition of human recombinant GST-tagged CDC25B expressed in Escherichia coli BL21 (DE3) using pNPP as substrate measured for 2 mins by colorimetric analysis	ic50	0.3800	uM
5-(4-nitrophenyl)-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.4000	uM
5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-enyl]naphthalene-1,4-dione	1517765: Inhibition of recombinant Cdc25B (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay	ic50	0.4000	uM
[(2R)-4-hexadecanoyl-3-hydroxy-5-oxo-2H-furan-2-yl]methyl N-(ethoxycarbonyliminomethylidene)carbamate	383135: Inhibition of cdc25B	ic50	0.4000	uM
methyl 2-(3-octadecanoyl-4,6-dioxo-1H-pyrrolo[3,4-d]pyrazol-5-yl)benzoate	480745: Inhibition of CDC25B	ic50	0.4100	uM
3-[4,6-dichloro-7-(3-methylbut-2-enyl)-1H-indol-3-yl]-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione	51890: Inhibitory constant of compound against Cell division cycle 25B was determined using mFP as a substrate	ki	0.4300	uM
6-chloro-7-(2-morpholin-4-ylethylamino)phthalazine-5,8-dione	51883: Inhibitory activity against recombinant human cell division cycle 25B	ic50	0.4300	uM
7-[2-(4-hydroxy-3-methoxyphenyl)ethylamino]quinoline-5,8-dione	51883: Inhibitory activity against recombinant human cell division cycle 25B	ic50	0.4500	uM
5-(2-fluorophenyl)-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.4500	uM
2-[(5Z)-5-[[6-[(2,4-dichlorophenyl)methoxy]naphthalen-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-(1H-indol-3-yl)propanoic acid	1551281: Inhibition of human recombinant GST-tagged CDC25B expressed in Escherichia coli BL21 (DE3) using pNPP as substrate measured for 2 mins by colorimetric analysis	ic50	0.4900	uM
methyl 4-(3-octadecanoyl-4,6-dioxo-1H-pyrrolo[3,4-d]pyrazol-5-yl)benzoate	480745: Inhibition of CDC25B	ic50	0.4900	uM
5-(4-nitrophenyl)-3-tetradecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.5000	uM
7-[(1-hydroxy-1-phenylpropan-2-yl)amino]quinoline-5,8-dione	51883: Inhibitory activity against recombinant human cell division cycle 25B	ic50	0.5100	uM
5-(3-methoxyphenyl)-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.5200	uM
5-(4-fluorophenyl)-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.5400	uM
5-(4-methoxyphenyl)-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.5400	uM
6-chloro-7-(2-morpholin-4-ylethylamino)isoquinoline-5,8-dione	51883: Inhibitory activity against recombinant human cell division cycle 25B	ic50	0.5900	uM
3-(6-hydroxyhexylamino)-2H-isoquinolin-1-one	1205064: Inhibition of His6-tagged human recombinant Cdc25B catalytic domain (350 to 566 residues) expressed in Escherichia coli BL21 (D3) using OMFP substrate after 30 mins by spectrophotometry	ic50	0.6400	uM
7-[2-(3,5-dibromo-4-hydroxyphenyl)ethylamino]quinoline-5,8-dione	51883: Inhibitory activity against recombinant human cell division cycle 25B	ic50	0.6400	uM
2,5-dihydroxy-3-[7-(3-methylbut-2-enyl)-1H-indol-3-yl]cyclohexa-2,5-diene-1,4-dione	51890: Inhibitory constant of compound against Cell division cycle 25B was determined using mFP as a substrate	ki	0.6400	uM
6-[(1-hydroxy-1-phenylpropan-2-yl)amino]quinoline-5,8-dione	51883: Inhibitory activity against recombinant human cell division cycle 25B	ic50	0.6700	uM
5-benzyl-3-octadecanoyl-1H-pyrrolo[3,4-d]pyrazole-4,6-dione	480745: Inhibition of CDC25B	ic50	0.7300	uM
3-[(4-methoxyphenyl)methylamino]-2H-isoquinolin-1-one	1205064: Inhibition of His6-tagged human recombinant Cdc25B catalytic domain (350 to 566 residues) expressed in Escherichia coli BL21 (D3) using OMFP substrate after 30 mins by spectrophotometry	ic50	0.7700	uM
3-(4-methylanilino)-2H-isoquinolin-1-one	1205064: Inhibition of His6-tagged human recombinant Cdc25B catalytic domain (350 to 566 residues) expressed in Escherichia coli BL21 (D3) using OMFP substrate after 30 mins by spectrophotometry	ic50	0.7700	uM
2-(3-hydroxy-6-oxoxanthen-9-yl)cyclohexane-1-carboxylic acid	1942245: Inhibition of CDC25B (unknown origin)	ic50	0.7800	uM

CTD chemical–gene interactions

101 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression, affects methylation, decreases activity (+1 more)	8
Valproic Acid	affects expression, decreases expression, increases expression	4
chromium hexavalent ion	increases abundance, decreases expression	3
sodium arsenate	affects cotreatment, increases reduction, decreases activity, increases abundance, increases expression	2
cobaltous chloride	decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Arsenic	increases abundance, increases expression, affects cotreatment, decreases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression, decreases reaction	2
Nickel	increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	increases methylation, affects expression	2
FR900359	decreases phosphorylation	1
echimidine	decreases expression, increases metabolic processing	1
TAK-243	increases sumoylation	1
dicrotophos	increases expression	1
lasiocarpine	decreases expression, increases metabolic processing	1
bisphenol A	decreases methylation	1
trichostatin A	decreases expression	1
cinnamaldehyde	decreases activity	1
riddelliine	decreases expression, increases metabolic processing	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
butyraldehyde	decreases expression	1
monomethylarsonic acid	decreases activity	1
perfluorooctanoic acid	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
fludarabine	affects cotreatment, increases phosphorylation	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
nickel sulfate	decreases expression	1

ChEMBL screening assays

166 unique, capped per target: 166 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1003157	Binding	Inhibition of Cdc25B (378-566) expressed in Escherichia coli at 50 uM	Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening. — J Med Chem

Cellosaurus cell lines

5 cell lines: 3 cancer cell line, 1 transformed cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7MA	Ubigene A-549 CDC25B KO	Cancer cell line	Male
CVCL_D8IQ	Ubigene HCT 116 CDC25B KO	Cancer cell line	Male
CVCL_D9BL	Ubigene HEK293 CDC25B KO	Transformed cell line	Female
CVCL_D9ZS	Ubigene HeLa CDC25B KO	Cancer cell line	Female
CVCL_RR08	MCF10A CDC25B (-/-)	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.